MedMen stock has underperformed the broader cannabis sector over the past one year. The stock has tumbled over 65% from its October peak price of $7.57.
MedMen Enterprises (CSE:MMEN) (OTCQX:MMNFF) has announced the opening of its second location in Sorrento Valley, San Diego California and its third-quarter results.
Sorrento Valley store
The location will be the 11th operational store the company is opening in California.
The Sorento Valley facility is strategically located in San Diego which is a major tourist destination. The opening of the store shows the company’s expansion strategy is in California which is estimated to have a cannabis market potential of $11 billion annually. Recently MedMen reported an estimated $100 million in annual sales in California and a 7% market share2.
[thrive_leads id=’8276′]
Q3 operating results
In the third quarter, MedMen reported systemwide revenue of $36.6 million that includes its retail operations and it also represents a 22% increase from the second quarter. The revenue recorded also includes the pending acquisition of PharmaCann as well as other smaller buyouts. In the third quarter, pro forma sales grew 11% to around $54.9 million compared to the third quarter last year. PharmaCann posted strong sales growth in the quarterly revenue growing to 15.5 million up from $9.8 million in the second quarter.
MedMen ended the quarter with around 82 licenses and 32 stores which includes pending acquisitions. In October 2018 when MedMen agreed to acquire PharmaCann for $682 million they had on 66 retail licenses. Although the expansion sounds to be a strong sign of progress the full quarterly results might reflect something different.
One thing that should raise eyebrows is how the company generated its Q3 results. Besides sales growth in Nevada and Arizona of 34% and 513% respectively most of its organic sales in 10 southern California locations declined. The 10 locations contributed a combined $24.9 million which was a partly 5% growth from Q2 which is alarming growth for a state that leads in recreational cannabis sales.
Gross margin also dropped from 53% in Q2 to 51% in Q3 despite the company reporting a $19.5 million gross profit. The company expects an operating loss of over $50 million following the trend in subsequent quarters.
